Breakthrough research in Manchester unveils new drug combo for rare KRAS-mutated lung cancer, boosting patient outcomes globally. Study in Cancer Discovery targets NSCLC, a major cause of cancer deaths New Drug Combo for KRAS Lung Cancer: Hope for Patients New...

Genentech’s next-generation KRAS G12C inhibitor, divarasib, demonstrated superior survival outcomes over sotorasib and adagrasib in a head-to-head study, maintaining a manageable and consistent safety profile Topline data were announced from a head-to-head phase 3 trial evaluating divarasib vs first generation...

Divarasib, an investigational next-generation KRAS G12C inhibitor, demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with approved first-generation KRAS G12C inhibitors sotorasib (Lumakras) and adagrasib (Krazati) in patients with previously treated, advanced...

Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial Author : alison doe | Published On : 06 Jul 2026 Genentech Divarasib Phase III Trial has delivered encouraging results after the company announced positive findings from its...

Divarasib, an oral next-generation KRAS G12C inhibitor, improved progression-free survival (PFS) and overall survival (OS) vs the approved first-generation KRAS G12C inhibitors sotorasib (Lumakras) and adagrasib (Krazati) in patients with previously treated KRAS G12C-mutated advanced or metastatic non–small cell lung...

Divarasib in KRAS G12C NSCLC improved PFS and OS versus approved KRAS inhibitors in the phase 3 KRASCENDO-1 trial Roche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLC Roche has reported positive top-line results from...

Roche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLC Roche has reported positive top-line results from KRASCENDO-1, a phase 3 study of divarasib in previously treated KRAS G12C-mutant advanced or metastatic non-small-cell lung cancer. The...

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial - Clinical Trials Roche has announced positive topline results from its Phase 3 Krascendo 1 study, demonstrating that its investigational next-generation KRAS G12C inhibitor, divarasib, significantly outperformed...

Swiss pharmaceutical company Roche has announced promising clinical trial data for its investigational drug, divarasib. The study evaluated the efficacy of the KRAS G12C inhibitor in patients with non-small cell lung cancer (NSCLC) who have previously undergone standard treatments, marking...

Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer -Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational...